The Thr17Ala polymorphism in human CTLA-4, which reduces the number of its N-glycan sites from two to one, is associated with multiple sclerosis (MS) risk via the attenuation of its surface retention [3,41,42]. This evidence concerns the gene CTLA4 and myeloid sarcoma.